

TABLE 1 Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or troglitazone

	Placebo group	Troglitazone group	P
<i>N</i>	122	114	
Clinical characteristics			
Age (years)	34.3 ± 6.5	34.9 ± 6.6	0.52
BMI (kg/m ²)	30.3 ± 5.3	30.6 ± 6.10	0.63
Waist-to-hip circumference ratio	0.86 ± 0.05	0.85 ± 0.06	0.19
Using hormonal contraceptives*	48%	43%	0.41
OGTT†			
Fasting glucose (mg/dl)	98.1 ± 9.1	98.7 ± 10.2	0.64
2-h glucose	154.0 ± 24.0	154.4 ± 27.0	0.97
Total glucose area (mg/dl × min × 10 ⁻³)‡	18.7 ± 2.0	18.9 ± 2.0	0.25
Impaired glucose tolerance§	72%	69%	0.66
Fasting insulin (U/ml)	16.0 ± 7.5	17.0 ± 10.8	0.82
Total insulin area (U/ml × min)‡	10,209 ± 5536	9,902 ± 6543	0.55
IVGTT			
Fasting glucose (mg/dl)	94.3 ± 10.4	94.8 ± 10.2	0.71
Kg (min ⁻¹ × 100)¶	1.48 ± 0.40	1.42 ± 0.39	0.23
Fasting insulin (U/ml)	18.7 ± 9.7	16.6 ± 9.5	0.05
Si(min ⁻¹ per U/ml × 10×4)#	2.28 ± 1.75	2.64 ± 1.70	0.05
AIKg (U/ml × min)**	569 ± 527	454 ± 360	0.18
Total insulin area (units/ml × min)‡	10,686 ± 5686	9,273 ± 5434	0.03
DI (SI × AIKg)††	983 ± 697	976 ± 717	0.99